TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20078462

Group type: EXPERIMENTAL
Intervention: Active rTMS (10 Hz frequency, 4.9 seconds per train, inter-train interval of 30 seconds, 20 trains per session, total 10 sessions)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 45
Study: 17944760

Group type: EXPERIMENTAL
Intervention: Yoga intervention (n = 28)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Supportive therapy intervention (n = 34)
Number of subjects: 62
Study: 15627538

Group type: COMPARATOR
Intervention: Ephedrine 10 mg
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Ephedrine 10 mg + Phenylephrine 40 microg
Number of subjects: 43
Study: 11877567

Group type: EXPERIMENTAL
Intervention: losartan, 50 mg/d
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study: 10200836

Group type: EXPERIMENTAL
Intervention: Natural context
Number of subjects: 40

Group type: COMPARATOR
Intervention: Simulated context
Number of subjects: 40
Study: 7773815

Group type: EXPERIMENTAL
Intervention: Active motion in combination with continuous passive motion (CPM)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Early active motion only (AM)
Number of subjects: 34
Study: 1449275

Group type: EXPERIMENTAL
Intervention: Ivermectin 20 micrograms kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ivermectin 50 micrograms kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ivermectin 100 micrograms kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ivermectin 200 micrograms kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Retreatment with the same dose of ivermectin after six months
Number of subjects: 60

Group type: COMPARATOR
Intervention: No retreatment at six months
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Side effects of ivermectin
Number of subjects: 60
Study: 3904380

Group type: EXPERIMENTAL
Intervention: Mexiletine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Procainamide
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mexiletine (Group II)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Amiodarone (after mexiletine)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Overall mortality in Group II
Number of subjects: 30
Study: 31760487

Group type: EXPERIMENTAL
Intervention: Early mobilization (immediate motion exercises)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Plaster immobilization (3 weeks)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Early mobilization
Number of subjects: 100

Group type: COMPARATOR
Intervention: Plaster immobilization
Number of subjects: 100
Study: 30193556

Group type: EXPERIMENTAL
Intervention: 50% Concurrent and 100% Terminal (50% C & 100% T)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 0% Concurrent and 100% Terminal (0% C & 100% T)
Number of subjects: 21

Group type: COMPARATOR
Intervention: 100% Concurrent and Terminal (100% C&T)
Number of subjects: 21
Study: 27392045

Group type: EXPERIMENTAL
Intervention: Gluten (20 g/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 26234970

Group type: EXPERIMENTAL
Intervention: Metacognitive instruction during ten two‐hour sessions
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional teaching method
Number of subjects: 40
Study: 24439191

Group type: EXPERIMENTAL
Intervention: Intravenous ceftazidime treatment
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no prophylaxis of antibiotics)
Number of subjects: 70
Study: 18997159

Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotic medications
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Management of elevated weight
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Psychiatrists with more than 12 patients with schizophrenia in their caseload
Number of subjects: 398
Study: 18620485

Group type: EXPERIMENTAL
Intervention: In vitro training model using chicken posterior trunks and porcine colons (Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Chicken skin model (Group B)
Number of subjects: 40
Study: 16364529

Group type: EXPERIMENTAL
Intervention: Dyslexic subjects
Number of subjects: 10

Group type: COMPARATOR
Intervention: Attention shifting task
Number of subjects: 10
Study: 12788251

Group type: EXPERIMENTAL
Intervention: Bipolar disorder subjects
Number of subjects: 26

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 26
Study: 10979643

Group type: EXPERIMENTAL
Intervention: ST + amino acid composition (glutaminic acid, glycine, cysteine)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ST + preductal
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard therapy (ST)
Number of subjects: 60
Study: 7612386

Group type: EXPERIMENTAL
Intervention: Plasmapheresis (PP) therapy only
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Plasmapheresis (PP) + high dose intravenous methylprednisolone therapy (pulse therapy)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Repeated Plasmapheresis (PP) + pulse therapy
Number of subjects: 7
Study: 2198157

Group type: EXPERIMENTAL
Intervention: Pirazolac (300-600 mg b.i.d.)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Indomethacin (25-50 mg t.i.d.)
Number of subjects: 119
Study: 490805

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation supplemented with partial venoarterial bypass (42 patients)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (48 patients)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Overall mortality in patients with pulmonary embolism and posttraumatic acute respiratory failure
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: ECMO support
Number of subjects: 90
Study: 31537689

Group type: EXPERIMENTAL
Intervention: KMT2D mutations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TP53 disruption
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MIPI-genetic index
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional or intensified chemotherapy
Number of subjects: 0
Study: 30444744

Group type: EXPERIMENTAL
Intervention: Methocarbamol
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 28516519

Group type: EXPERIMENTAL
Intervention: Supervised exercise training (ET) 3 times/week for 12 months
Number of subjects: 320

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 320
Study: 26395866

Group type: EXPERIMENTAL
Intervention: MDMA (125 mg orally)
Number of subjects: 16
Study: 23436087

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastrectomy for gastric cancer
Number of subjects: 164

Group type: COMPARATOR
Intervention: Roux-en-Y gastric bypass for morbid obesity
Number of subjects: 164
Study: 21515839

Group type: EXPERIMENTAL
Intervention: First gluten exposure at age 12 months (late-exposure group)
Number of subjects: 150

Group type: COMPARATOR
Intervention: First gluten exposure at age 6 months (control group)
Number of subjects: 150
Study: 18380975

Group type: EXPERIMENTAL
Intervention: Direct composite inlays
Number of subjects: 163

Group type: COMPARATOR
Intervention: Traditional composite fillings
Number of subjects: 163
Study: 16984550

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with propofol
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with midazolam
Number of subjects: 121

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 121
Study: 12975594

Group type: EXPERIMENTAL
Intervention: Orbiofan (50 mg BID)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10947150

Group type: COMPARATOR
Intervention: SMART methodology
Number of subjects: 240

Group type: COMPARATOR
Intervention: SMART models for renal and liver function indicators
Number of subjects: 240

Group type: COMPARATOR
Intervention: SMART hematologic/coagulation models
Number of subjects: 240

Group type: COMPARATOR
Intervention: SMART dichotomous models
Number of subjects: 240
Study: 9172027

Group type: EXPERIMENTAL
Intervention: Priming dose of rocuronium 0.06 mg/kg followed two minutes later by an intubating dose of rocuronium 0.54 mg/kg
Number of subjects: 42

Group type: COMPARATOR
Intervention: Saline placebo injection followed two minutes later by rocuronium 0.6 mg/kg
Number of subjects: 42
Study: 8115731

Group type: EXPERIMENTAL
Intervention: Tono-Pen XL
Number of subjects: 40

Group type: COMPARATOR
Intervention: Manometer readings
Number of subjects: 40
Study: 3549843

Group type: EXPERIMENTAL
Intervention: Indomethacin, 100 mg per day
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Placebo capsules
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 6
Study: 29734566

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO₂)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 71
Study: 26915984

Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg bid
Number of subjects: 1231

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1231
Study: 23685020

Group type: EXPERIMENTAL
Intervention: Charlson comorbidity index (CCI)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Hypertension (HTN)
Number of subjects: 221

Group type: COMPARATOR
Intervention: CCI ≥ 7 vs CCI = 6
Number of subjects: 221
Study: 23093731

Group type: EXPERIMENTAL
Intervention: Intervention arm in Gothenburg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm in Gothenburg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention arm in Rotterdam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm in Rotterdam
Number of subjects: 0
Study: 20821816

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 0
Study: 18432483

Group type: EXPERIMENTAL
Intervention: Idea improvement during recall‐own plagiarism task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Independent ratings during generate‐new plagiarism task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Feedback on idea quality from independent judges
Number of subjects: 0
Study: 15730413

Group type: EXPERIMENTAL
Intervention: Low-dose rhGH (0.1 U/kg/day)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: High-dose rhGH (0.2 U/kg/day)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 12964121

Group type: EXPERIMENTAL
Intervention: HIV(+)/HTLV-II(-)
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: HIV(-)/HTLV-II(+)
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: HIV(+)/HTLV-II(+)
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: HTLV-II infection in white subjects
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Overall mean HCV load
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Study site
Number of subjects: 385
Study: 10546695

Group type: EXPERIMENTAL
Intervention: Multiple short‐bout exercise with home exercise equipment (SBEQ)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Multiple short‐bout exercise (SB)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Long‐bout exercise (LB)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Exercise participation (more than 200 min/wk)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: All groups (LB, SB, SBEQ)
Number of subjects: 148
Study: 8655980

Group type: EXPERIMENTAL
Intervention: Intraderal BCG
Number of subjects: 0

Group type: COMPARATOR
Intervention: Percutaneous BCG
Number of subjects: 0
Study: 1675849

Group type: EXPERIMENTAL
Intervention: Terfenadine (300 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 6384844

Group type: EXPERIMENTAL
Intervention: 0.5 mg PGE2 gel
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.25 mg PGE2 gel
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 45
Study: 30340932

Group type: EXPERIMENTAL
Intervention: Early routine treatment (ERT)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Conservative treatment (CT)
Number of subjects: 202
Study: 30297352

Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) at 660 nm, power 100 mW, radiant exposure: 177 J/cm2, 0.5J per point, applied 2 times/week for 1 month.
Number of subjects: 44

Group type: COMPARATOR
Intervention: Clobetasol propionate 0.05%, applied three times a day for 30 days.
Number of subjects: 44
Study: 26258496

Group type: EXPERIMENTAL
Intervention: Daylight-mediated photodynamic therapy (DL-PDT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Light-emitting diode photodynamic therapy (LED-PDT)
Number of subjects: 70
Study: 25151042

Group type: EXPERIMENTAL
Intervention: Quadrivalent meningococcal conjugate vaccine (MCV4) in PSV-exposed/MCV4 group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MPSV4 in PSV-exposed/MPSV4 group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MCV4 in PSV-naïve group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable (control group)
Number of subjects: 0
Study: 21481104

Group type: EXPERIMENTAL
Intervention: Ultraviolet radiation (UVR)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Sham UVR (filtered UVR)
Number of subjects: 7
Study: 20027351

Group type: COMPARATOR
Intervention: Ultralow doses of antibodies to human IFN-gamma (anaferon pediatric formulation and anaferon)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17363130

Group type: EXPERIMENTAL
Intervention: Compression ratio 30:2
Number of subjects: 130

Group type: COMPARATOR
Intervention: Compression ratio 15:2
Number of subjects: 130
Study: 15295747

Group type: EXPERIMENTAL
Intervention: 30-minute cryotherapy treatment (1-kg ice bag application)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No ice treatment (control)
Number of subjects: 30
Study: 11591611

Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 281

Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 281
Study: 9677555

Group type: EXPERIMENTAL
Intervention: Peribulbar injection (9 ml of anaesthetic from an inferotemporal site)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Retrobulbar injection (local anaesthetic through conjunctiva and facialis blockade)
Number of subjects: 59
Study: 8303829

Group type: EXPERIMENTAL
Intervention: Kicking to move a block mobile displaying horizontal and vertical lines (textons) arranged as L, T, or +
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delayed recognition tested at 0, 1, 3, 5, 7, or 9 days
Number of subjects: 0
Study: 2467588

Group type: EXPERIMENTAL
Intervention: Morphine 1.8 mg iv every 8 min as required
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Meperidine 18 mg iv every 8 min as required
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Oxymorphone 0.3 mg iv every 8 min as required
Number of subjects: 75
Study: 29439526

Group type: EXPERIMENTAL
Intervention: Synergy 1 (10 g/day)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (maltodextrin; 7 g/day)
Number of subjects: 34
Study: 28224442

Group type: COMPARATOR
Intervention: SAP (Strength, Agility, and Secondary Prevention treatment)
Number of subjects: 40

Group type: COMPARATOR
Intervention: SAP+PERT (Strength, Agility, and Secondary Prevention treatment plus Perturbation Training)
Number of subjects: 40

Group type: COMPARATOR
Intervention: SAP
Number of subjects: 40

Group type: COMPARATOR
Intervention: SAP+PERT
Number of subjects: 40
Study: 25670755

Group type: EXPERIMENTAL
Intervention: Custom-developed asthma decision support system integrated within MOXXI
Number of subjects: 4447

Group type: COMPARATOR
Intervention: Control group using the Medical Office of the 21st century (MOXXI) system
Number of subjects: 4447
Study: 22441680

Group type: EXPERIMENTAL
Intervention: Nasal stent
Number of subjects: 20

Group type: COMPARATOR
Intervention: No stenting
Number of subjects: 20
Study: 21503122

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg one hour before anesthesia induction and 200 mg q12 h for five consecutive days after surgery
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 37
Study: 19451500

Group type: EXPERIMENTAL
Intervention: Teledermatologic consultation
Number of subjects: 631

Group type: COMPARATOR
Intervention: Usual practice (control)
Number of subjects: 631
Study: 16679325

Group type: EXPERIMENTAL
Intervention: Auricular electro-acupuncture (EA, n = 32)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture (A, n = 32)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Conventional analgesia with remifentanil (CO, n = 30)
Number of subjects: 94
Study: 15358701

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) at 1,000 microg.day(‐1) followed by reductions to 500, 200, and 100 microg.day(‐1)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) at 1,000 and 500 microg.day(‐1)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) at 200 microg.day(‐1)
Number of subjects: 55
Study: 11301674

Group type: EXPERIMENTAL
Intervention: Comprehensive palliative care
Number of subjects: 183

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 183
Study: 9280187

Group type: EXPERIMENTAL
Intervention: Milk
Number of subjects: 22

Group type: COMPARATOR
Intervention: Egg white
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: TNF-alpha concentration
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: IL-6 concentration
Number of subjects: 22
Study: 8100911

Group type: EXPERIMENTAL
Intervention: Intravenous morphine given at induction of anaesthesia (iv pre)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intramuscular morphine given 1 hour before operation (im pre)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous morphine given at closure of the peritoneum (iv post)
Number of subjects: 60
Study: 3520204

Group type: EXPERIMENTAL
Intervention: Cianidanol (1.5 g daily for 2 weeks, then 2.25 g for 14 weeks)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Cianidanol
Number of subjects: 338
Study: 30346977

Group type: EXPERIMENTAL
Intervention: Tailored model for hierarchical inference
Number of subjects: 0

Group type: COMPARATOR
Intervention: Generically powerful variational method for hierarchical inference
Number of subjects: 0
Study: 27883319

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Walking (combined with HRT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Walking (placebo group)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Combination of HRT and walking
Number of subjects: 22
Study: 24337601

Group type: EXPERIMENTAL
Intervention: PET imaging combined with comprehensive lifestyle modification
Number of subjects: 1300
Study: 22958678

Group type: EXPERIMENTAL
Intervention: Practice nurse-GP partnership care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 20980048

Group type: EXPERIMENTAL
Intervention: mOPV1
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: bOPV
Number of subjects: 900

Group type: COMPARATOR
Intervention: tOPV
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: mOPV2
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: mOPV3
Number of subjects: 900
Study: 17396068

Group type: EXPERIMENTAL
Intervention: Nisoldipine coat-core (CC)
Number of subjects: 0
Study: 15567534

Group type: EXPERIMENTAL
Intervention: Shoulder impingement group during lead limb transfer
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Shoulder impingement group during trail limb transfer
Number of subjects: 23

Group type: COMPARATOR
Intervention: No shoulder impingement group during lead limb transfer
Number of subjects: 23
Study: 12032013

Group type: EXPERIMENTAL
Intervention: Music group (n = 48)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (n = 45)
Number of subjects: 93
Study: 10461716

Group type: EXPERIMENTAL
Intervention: Head positioned on the down-side
Number of subjects: 39

Group type: COMPARATOR
Intervention: Head positioned on the up-side
Number of subjects: 39
Study: 7604380

Group type: EXPERIMENTAL
Intervention: Total Parenteral Nutrition (TPN) in patients with sepsis
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Total Parenteral Nutrition (TPN) in ambulatory patients receiving HPN
Number of subjects: 8
Study: 1970738

Group type: EXPERIMENTAL
Intervention: Bupivacaine-morphine mixture (0.125% bupivacaine with morphine 0.05 mg kg‐1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bupivacaine alone (0.125% bupivacaine)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (Bupivacaine-morphine mixture and Bupivacaine alone)
Number of subjects: 30
Study: 396690

Group type: EXPERIMENTAL
Intervention: amoxycillin 1.5 g daily
Number of subjects: 25

Group type: COMPARATOR
Intervention: ampicillin 4 g daily
Number of subjects: 25
Study: 31486447

Group type: EXPERIMENTAL
Intervention: 500 mg resveratrol per day
Number of subjects: 56
Study: 29106881

Group type: COMPARATOR
Intervention: Standard verbal post-operative instructions
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Video teaching tool along with standard verbal instructions
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Video teaching tool only
Number of subjects: 99
Study: 26499867

Group type: EXPERIMENTAL
Intervention: Cognitively challenging mobility exercise program for 6 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Group education program for 6 weeks
Number of subjects: 0
Study: 23993887

Group type: EXPERIMENTAL
Intervention: Bilateral salpingectomy
Number of subjects: 30

Group type: COMPARATOR
Intervention: No salpingectomy
Number of subjects: 30
Study: 21247627

Group type: EXPERIMENTAL
Intervention: Exemestane alone (25 mg once a day, orally)
Number of subjects: 9779

Group type: COMPARATOR
Intervention: Sequential treatment (tamoxifen 20 mg once a day, orally for 5 years followed by exemestane)
Number of subjects: 9779

Group type: COMPARATOR
Intervention: Sequential treatment
Number of subjects: 9779

Group type: EXPERIMENTAL
Intervention: Exemestane alone
Number of subjects: 9779
Study: 19930904

Group type: EXPERIMENTAL
Intervention: Immunotherapy with Ulinastatin plus Thymosin‐alpha(1)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional therapy (antibiotics and fluid resuscitation)
Number of subjects: 70
Study: 18046737

Group type: EXPERIMENTAL
Intervention: Fitness Game (experimental intervention)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Non-legal programming (control intervention)
Number of subjects: 28
Study: 15917722

Group type: EXPERIMENTAL
Intervention: HESA‐A (50 mg/kg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24